Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

10X Genomics Inc

Healthcare US TXG

33.5USD
1.34(4.17%)

Last update at 2026-06-04T20:08:00Z

Day Range

32.1635.65
LowHigh

52 Week Range

6.7824.85
LowHigh

Fundamentals

  • Previous Close 32.16
  • Market Cap1156.23M
  • Volume4084365
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-146.88200M
  • Revenue TTM624.66M
  • Revenue Per Share TTM5.15
  • Gross Profit TTM 427.01M
  • Diluted EPS TTM-1.3

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -161.97100M -53.71500M -534.47600M -31.03300M -112.39800M
Minority interest - - - - 0.00000M
Net income -166.00000M -58.22300M -542.73100M -31.25100M -112.48500M
Selling general administrative 298.30M 257.56M 202.33M 130.83M 87.94M
Selling and marketing expenses - - - - -
Gross profit 396.02M 416.40M 240.38M 184.86M 117.65M
Reconciled depreciation 33.01M 28.25M 19.02M 7.07M 3.90M
Ebit -167.94400M -52.91300M -85.32400M -29.07100M -17.04600M
Ebitda -161.49500M -53.50900M -82.45500M -26.45200M -13.14100M
Depreciation and amortization 6.45M -0.59600M 2.87M 2.62M 3.90M
Non operating income net other 6.45M -0.59600M 1.35M - 0.00000M
Operating income -167.94400M -52.91300M -85.32400M -29.07100M -110.76400M
Other operating expenses 684.35M 543.40M 384.17M 274.96M 164.13M
Interest expense 0.48M 0.87M 1.68M 3.08M 2.41M
Tax provision 4.03M 4.51M 8.26M 0.22M 0.09M
Interest income 6.65M 0.21M 1.53M 2.81M 1.02M
Net interest income 6.17M -0.66000M -0.15000M -0.27400M -1.38500M
Extraordinary items - - - - 0.00000M
Non recurring - -0.66000M 448.82M - 0.00000M
Other items - - - - 0.00000M
Income tax expense 4.03M 4.51M 8.26M 0.22M 0.09M
Total revenue 516.41M 490.49M 298.85M 245.89M 146.31M
Total operating expenses 563.97M 469.31M 325.70M 213.93M 135.47M
Cost of revenue 120.39M 74.09M 58.47M 61.03M 28.66M
Total other income expense net 5.97M -0.80200M -449.15200M -1.96200M -93.19200M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -166.00000M -58.22300M -542.73100M -31.25100M -112.48500M
Net income applicable to common shares -166.00000M -58.22300M -542.73100M -31.25100M -112.48500M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 918.64M 965.14M 1028.98M 1018.83M 929.34M
Intangible assets 15.67M 16.62M 22.86M 25.40M 22.35M
Earning assets - - - - -
Other current assets 20.02M 18.79M 16.58M 14.92M 29.60M
Total liab 208.50M 224.10M 223.24M 201.26M 190.27M
Total stockholder equity 710.13M 741.04M 805.74M 817.57M 739.07M
Deferred long term liab - - - - -
Other current liab 64.91M 86.75M 92.45M 82.53M 103.01M
Common stock 0.00200M 0.00200M 0.00200M 0.00200M 0.00200M
Capital stock 0.00200M 0.00200M 0.00200M 0.00200M 0.00200M
Retained earnings -1467.04700M -1284.42000M -1029.32100M -863.32100M -805.09800M
Other liab - - 6.14M 14.05M 15.10M
Good will 4.51M 4.51M 4.51M 4.51M -
Other assets - - 7.37M 10.92M 82.14M
Cash 344.07M 359.28M 219.75M 587.45M 663.60M
Cash and equivalents - - - - -
Total current liabilities 117.63M 127.16M 130.96M 110.36M 118.13M
Current deferred revenue 20.66M 13.15M 7.87M 5.34M 4.47M
Net debt -261.45400M -263.91400M -124.57000M -505.46900M -600.62500M
Short term debt 9.29M 11.52M 9.04M 5.13M 5.94M
Short long term debt - - - - -
Short long term debt total 82.61M 95.37M 95.18M 81.98M 62.98M
Other stockholder equity 2177.67M 2025.89M 1839.40M 1680.87M 1544.22M
Property plant equipment - - 289.33M 230.41M 72.84M
Total current assets 584.39M 596.02M 635.03M 747.59M 774.37M
Long term investments - - - - -
Net tangible assets - - 778.37M 787.66M 739.07M
Short term investments 49.34M 29.41M 210.24M - -
Net receivables 87.86M 114.83M 104.21M 85.25M 51.21M
Long term debt - - - - -
Inventory 83.11M 73.71M 81.63M 59.97M 29.96M
Accounts payable 12.91M 15.74M 21.60M 17.35M 4.71M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.49300M -0.42900M -4.33500M 0.02M -0.05000M
Additional paid in capital - - - - -
Common stock total equity - - 0.00200M 0.00200M 0.00200M
Preferred stock total equity - - - - -
Retained earnings total equity - - -1029.32100M -863.32100M -805.09800M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.13M 3.06M 7.37M 10.92M 12.80M
Deferred long term asset charges - - - - -
Non current assets total 334.25M 369.12M 393.94M 271.24M 154.97M
Capital lease obligations 82.61M 95.37M 95.18M 81.98M 62.98M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -350.88700M -106.72900M -38.39400M -42.76700M -6.70900M
Change to liabilities 7.37M 21.84M 17.31M 5.54M 4.26M
Total cashflows from investing activities -350.88700M -106.72900M -38.39400M -42.76700M -6.70900M
Net borrowings -5.40900M -5.02800M -37.10400M -37.10400M 18.74M
Total cash from financing activities 15.82M 35.30M 468.91M 414.59M 105.37M
Change to operating activities -8.48500M -35.89100M -12.18600M 51.21M 42.23M
Net income -166.00000M -58.22300M -542.73100M -31.25100M -112.48500M
Change in cash -368.72000M -92.57100M 212.15M 406.40M 22.23M
Begin period cash flow 596.07M 688.64M 476.49M 70.09M 47.86M
End period cash flow 227.35M 596.07M 688.64M 476.49M 70.09M
Total cash from operating activities -33.60600M -21.37300M -217.89800M 34.63M -76.40900M
Issuance of capital stock 0.00000M 0.00000M 482.27M 410.82M 86.63M
Depreciation 33.01M 28.25M 19.02M 7.07M 3.90M
Other cashflows from investing activities -4.00000M -5.45100M -1.72800M - 0.00000M
Dividends paid - - - - 0.00000M
Change to inventory -21.19200M -30.13200M -14.60100M -6.69900M -3.73200M
Change to account receivables -18.94800M -34.04100M -17.84700M -5.28400M -14.74700M
Sale purchase of stock 21.23M 40.33M 506.01M 0.00000M 0.00000M
Other cashflows from financing activities -5.40900M 35.30M 17.89M 14.77M 104.34M
Change to netincome 137.93M 96.04M 356.18M 13.95M 3.70M
Capital expenditures 131.66M 101.28M 38.39M 42.77M 6.71M
Change receivables -18.94800M -34.04100M -17.84700M - 0.00000M
Cash flows other operating 0.99M -37.97900M -30.23600M - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes -368.67600M -92.80500M 212.61M - 0.00000M
Change in working capital -39.41700M -87.44500M -50.38100M 44.76M 28.02M
Stock based compensation 136.85M 95.96M 48.63M 13.33M 2.66M
Other non cash items 1.96M 0.08M 306.02M 0.10M 1.25M
Free cash flow -165.26700M -122.65100M -256.29200M -8.14000M -83.11800M

Peer Comparison

Sector: Healthcare Industry: Health Information Services

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TXG
10X Genomics Inc		 1.34 4.17% 33.50 - 196.08 1.85 1.64 1.30 -40.6858
VEEV
Veeva Systems Inc Class A		 -0.12 0.07% 178.60 54.61 33.22 12.83 6.73 11.14 58.84
MTHRF
M3 Inc		 - -% 8.55 29.72 25.00 0.05 4.38 0.04 0.12
MTHRY
M3 Inc		 0.08 1.70% 4.79 31.84 26.25 0.05 4.60 0.04 0.12
BTSG
BrightSpring Health Services, Inc. Common Stock		 -3.48 5.72% 57.40 100.22 40.65 0.69 4.92 0.92 25.80

Reports Covered

Stock Research & News

View All

Profile

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

10X Genomics Inc

6230 Stoneridge Mall Road, Pleasanton, CA, United States, 94588-3260

Key Executives

Name Title Year Born
Dr. Serge Saxonov Ph.D. Co-Founder, CEO & Director 1977
Dr. Benjamin J. Hindson Ph.D. Co-Founder, Pres, Chief Scientific Officer & Director 1975
Mr. Justin J. McAnear Chief Financial Officer 1976
Mr. Eric S. Whitaker Esq. Chief Legal Officer 1967
Mr. Michael Schnall-Levin Founding Scientist & CTO NA
Ms. Cassie Corneau Mang. of Investor Relations and Strategic Fin. NA
Mr. Jonathan Schimmel VP of Global Support & Sales Operations NA
Ms. Rebecca Port Chief People Officer NA
Ms. Ruth De Backer Chief Bus. Officer 1977
Mr. Jim Wilbur Ph.D. Chief Commercial Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions